At least they seem to be following some sort of plan. You will need to ask who wrote it and can survivors provide input.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=135003&CultureCode=en
The COUNTERSTROKE consortium, led by researchers at Karolinska
Institutet in Sweden, today initiates a six million Euro EU funded
collaboration to develop novel therapeutics to treat stroke.
Stroke
and other conditions related to a decreased oxygen supply to the brain
are the third most common cause of death in Europe. One out of three
stroke incidents lead to permanent damage, and stroke is a major cause
of adult disability.
The COUNTERSTROKE consortium, which consists
of six European research institutions and companies, is pleased to
announce the initiation of a grant funded research for developing new
therapeutics in the field of stroke. The consortium has received a six
million Euro grant from EU’s Seventh Framework Program (FP7-Health) to
develop molecules targeting the pro-inflammatory protein HMGB1.
“A
key success factor for this exciting project is the network of
specialists we have put together. We have expertise in the fundamental
biology of HMGB1 and its role in stroke, industrial partners that can
bring the biopharmaceutical into the clinic and clinicians focused on
improving the care of stroke patients”, comments Associate professor
Helena Erlandsson Harris, based at the Center for Molecular Medicine
(CMM) and the Department of Medicine, Solna at Karolinska
Institutet, and the coordinator of COUNTERSTROKE.
During the
fifteen years HMGB1 has been studied, it has become evident that HMGB1
plays an important role in several inflammatory conditions, including
stroke, and that a blockade of HMGB1 could reduce the symptoms. The
COUNTERSTROKE project thus has the potential to be beneficial not only
to stroke patients but also individuals suffering from chronic diseases
such as rheumatism and lupus and also acute inflammatory conditions such
as sepsis.
The consortium will develop Affibody® molecules specific for HMGB1 for the treatment of stroke.
“It
is a great honor to be part of the COUNTERSTROKE consortium and we are
deeply impressed by the knowledge and capacity of our collaborators. It
is a privilege to contribute with drug discovery and development
competence in this prestigious project”, says David Bejker, CEO of
Affibody AB.
The Affibody® molecules are a new class
of biopharmaceuticals which mimics antibodies with regards to
selectivity and strong binding to the target protein with the advantage
that they are significantly smaller and are inherently inert, meaning
that they do not have any functions that involve activation of the
body's immune system. Thus these molecules targeting HMGB1 could become a
promising treatment for stroke patients.
The novel aspect of the
project is the potential to prolong the time frame for effective
treatment of the stroke, which today is around four hours, in order to
minimize the brain damage following the lack of oxygen supply.
http://ki.se/pressroom
No comments:
Post a Comment